Seeking Alpha讨论直觉外科财报后下跌是否为买入机会

Intuitive Surgical (ISRG) reported strong second-quarter 2026 results, but its stock plunged on concerns about slowing domestic procedure growth. Despite beating both top- and bottom-line consensus estimates—with revenue of $2.89B (up 18.4% YoY) and adjusted EPS of $2.80 that exceeded expectations by $0.30—shares fell as U.S. da Vinci procedure growth moderated to 12% YoY, spooking investors accustomed to stellar growth rates.
Still, despite the immediate market panic, analyst sentiment remains mixed, and several prominent experts maintain their bullish outlook, arguing that the long-term compounding story is intact.
Bullish investors emphasized the robust operational metrics, highlighting that worldwide procedure growth reached 16% and gross margin expanded to a healthy 70.0% non-GAAP. They pointed to strong recurring revenue streams comprising ~85% of total sales and resilient system placements of 468 da Vinci units in Q2, an 18% YoY jump. The installed base growth for da Vinci remained steady at 12%, while Ion installed base grew 21%.
Pessimists, however, focused on structural headwinds impacting growth. They expressed concern over the expiry of ACA enhanced tax credits on December 31, which restricted patients' health insurance coverage. Additionally, GLP-1 weight loss drugs are causing a structural high-single-digit decline in bariatric procedures, presenting a more permanent challenge to certain surgical volumes.
Here's a breakdown of what some analysts had to say:
Bay Area Ideas, Rating: Buy: "With the installed base results looking quite robust for their flagship da Vinci system, I believe it is safe to say that overall adoption has remained quite solid despite some softness in procedure growth. The health insurance-related weakness in U.S. procedures is unlikely to derail the long-term growth outlook for Intuitive Surgical in my view." - Intuitive Surgical Is Getting Punished For No Good Reason
Kenio Fontes, Rating: Buy: "Even if the market did not like the Q2 earnings, I considered it a quite solid quarter; the company continues improving operationally and guiding good growth for 2026... it is very far from being a bad quarter. In fact, I would say that as Intuitive Surgical keeps improving its operational indicators, growing revenue in the high-mid teens, and maintaining strong margins, this quarter only reinforces that the company is really a potential compounder." - Intuitive Surgical Q2: The Market Is Missing The Bigger Picture
The Alpha Analyst, Rating: Buy: "The fundamentals have deteriorated, but the valuations have overreacted, creating an opportunity that strong fundamentals could not in May last year... I recommend initiating starter positions and keeping some dry powder aside to keep accumulating ISRG stock if the current momentum on the downside pulls the stock back further." - Intuitive Surgical: The Correction Has Done The Work The Fundamentals Could Not
Intuitive Surgical currently carries a Hold rating from Seeking Alpha's quant system. While the company's growth grades have raised some eyebrows, its superb profitability margins remain a clear highlight, keeping its overall grade balanced.
Profitability: The company continues to demonstrate elite profitability, earning an A+ grade, supported by a non-GAAP gross profit margin that reached 70.0% in Q2, while non-GAAP operating margin expanded by 330 basis points YoY to 42.1%.
Valuation: Valuation receives a weak grade of D-, though multiple compressions have significantly reduced its forward P/E multiple from historical premiums of around 60x down to ~33x forward earnings, offering a far better margin of safety than in previous quarters.
Growth: Growth metrics are graded modestly at C+, reflecting a trajectory slowdown with total revenue growing by 19% YoY to $2.89B, compared to the 23% YoY growth rate logged in Q1.
Momentum: Momentum receives a D grade, following the post-earnings selloff, which has driven the stock down nearly 30% to 38% from its recent multiyear peaks.
Earnings Revisions: Earnings revisions score a solid A-, supported by the company beating its adjusted EPS target by $0.30 to post $2.80 in adjusted earnings per share.
Intuitive Surgical (ISRG) released its Q2 2026 earnings report, posting a revenue beat. This top-line success was driven by instruments and accessories revenue of $1.73B, powered by a 15% rise in da Vinci procedure volumes and a stellar 36% jump in Ion procedure volumes. Non-GAAP gross margin improved to 70.0%, and non-GAAP operating margin expanded by 330 basis points YoY to 42.1%.
However, worries about the U.S. payer mix and patient insurance coverage drove a steep post-earnings selloff of around 9% to 14% in the sessions following the call. Shares fell alongside related healthcare giants like HCA Healthcare (HCA), which had warned of similar premium shifts due to the expiry of enhanced ACA subsidies on December 31. CFO Jamie Samath noted during the earnings call that the company saw "a slight moderation in procedure growth rate that started in Q1" for benign procedures, a subset of which can be deferred.
Looking ahead, the Sunnyvale, California-based MedTech company reaffirmed its full-year 2026 worldwide da Vinci procedure growth of 13.5% to 15.5%, expecting results closer to the midpoint. It also adjusted its non-GAAP gross margin range favorably to 68.0% to 69.0% (including an estimated tariff impact of 1.0% of revenue) and lowered its non-GAAP operating expense growth expectations to a range of 11% to 13%.